COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other Events
Item8.01
| Other Events |
On March2, 2017, Coherus BioSciences, Inc. issued a press release
reporting that CHS-1420, its proposed biosimilar of adalimumab
(Humira), met the primary endpoint in a clinical pharmacokinetic
bioequivalence study that compared CHS-1420 to Humira in healthy
subjects. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by
reference into this Item8.01.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
| 99.1 | Press release dated March2, 2017. |
About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs). COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Recent Trading Information
COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) closed its last trading session up +0.65 at 25.45 with 1,061,888 shares trading hands.
